NCT05376410

Brief Summary

We planed to evaluate soluble the triggering receptors expressed on myeloid cell-1 (s TREM-1) levels in serum of pregnant women diagnosed with placenta accreta spectrum and compare it with healthy pregnant women's s TREM-1 serum levels.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 14, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

May 11, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 17, 2022

Completed
15 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2022

Completed
Last Updated

May 17, 2022

Status Verified

May 1, 2022

Enrollment Period

7 months

First QC Date

May 11, 2022

Last Update Submit

May 11, 2022

Conditions

Placenta Accreta, Third Trimester

Keywords

Placenta Accreta, sTREM-1

Outcome Measures

Primary Outcomes (1)

  • sTREM-1 levels

    sTREM-1 levels in maternal serum

    after 12 hours fasting

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant.
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

3rd trimester pregnancies diagnosed with placenta accreta spectrum.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Necmettin Erbakan University Meram Medicine Faculty

Konya, Turkey (Türkiye)

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

blood serum.

MeSH Terms

Conditions

Placenta Accreta

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPlacenta Diseases

Central Study Contacts

hasan energin, dr.

CONTACT

00905530619041hasanenergin@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
asistan professor

Study Record Dates

First Submitted

May 11, 2022

First Posted

May 17, 2022

Study Start

November 14, 2021

Primary Completion

June 1, 2022

Study Completion

July 1, 2022

Last Updated

May 17, 2022

Record last verified: 2022-05

Locations

TU(1)